Caspase-9 as a target for Pneumocystis pneumonia therapy

Journal of Eukaryotic Microbiology

Volumn 53, Issue SUPPL. 1, 2006, Pages

  Lasbury, Mark E ^a   Wang, Shao Hung ^a   Zhang, Chen ^a   Liao, Chung Ping ^a   Durant, Pamela J ^a   Tschang, Dennis ^a   Lee, Chao Hung ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; DNA FRAGMENT; ENZYME INHIBITOR;

RESPIRATORY DISEASE;

ANIMAL; APOPTOSIS; BIOSYNTHESIS; CELL CULTURE; CONFERENCE PAPER; DRUG ANTAGONISM; FEMALE; IMMUNE DEFICIENCY; IMMUNOBLOTTING; IMMUNOLOGY; LEUKOCYTE COUNT; LUNG LAVAGE; MACROPHAGE; NICK END LABELING; PATHOLOGY; PNEUMOCYSTIS; PNEUMOCYSTIS PNEUMONIA; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; APOPTOSIS; BRONCHOALVEOLAR LAVAGE; CASPASE 10; CASPASE 3; CASPASE 8; CASPASE 9; CELLS, CULTURED; DNA FRAGMENTATION; ENZYME INHIBITORS; FEMALE; IMMUNOBLOTTING; IMMUNOCOMPROMISED HOST; IN SITU NICK-END LABELING; LEUKOCYTE COUNT; MACROPHAGES; PNEUMOCYSTIS; PNEUMONIA, PNEUMOCYSTIS; RATS; RATS, SPRAGUE-DAWLEY;

PNEUMOCYSTIS;

EID: 33751365685     PISSN: 10665234     EISSN: 15507408     Source Type: Journal    
DOI: 10.1111/j.1550-7408.2006.00205.x     Document Type: Conference Paper

References (14)

1. Allegra, C. J., Chabner, B. A., Tuazon, C. U., Ogata-Arakaki, D., Baird, B., Drake, J. C. & Masur, H. 1988. Treatment of Pneumocystis carinii pneumonia with trimetrexate in acquired immunodeficiency syndrome (AIDS). Sem. Oncol., 15:46-49.
2. Bartlett, M. S., Fishman, J. A., Queener, S. F., Durkin, M. M., Jay, M. A. & Smith, J. W. 1988. New rat model of Pneumocystis carinii infection. J. Clin. Microbiol., 26:1100-1102.
3. Han, B. H., Xu., D., Choi, J., Han, Y., Xanthoudakis, S., Roy, S., Tam, J., Vaillancourt, J., Colucci, J., Siman, R., Giroux, A., Robertson, G. S., Zamboni, R., Nicholson, D. W. & Holtzman, D. M. 2002. Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death after neonatal hypoxic-ischemic brain injury. J. Biol. Chem., 277:30128-30136.
4. Iliades, P., Meshnick, S. R. & Macreadie, I. G. 2005. Mutations in the Pneumocystis jirovecii DHPS gene confer cross-resistance to sulfa drugs. Antimicrob. Agents Chem., 49:741-748.
5. Jung, A. C. & Paauw, D. S. 1994. Management of adverse reactions to trimethoprim-sulfamethoxazole in human immunodeficiency virus-infected patients. Arch. Intern. Med., 154:2402-2406.
6. Lasbury, M. E., Durant, P. J. & Lee, C. H. 2003. Transtracheal inoculation of Pneumocystis carinii in immunocompetent animals. J. Eukaryot. Microbiol., 50:643-644.
7. Lasbury, M. E., Durant, P. J., Bartlett, M. S., Smith, J. W. & Lee, C. H. 2003. Correlation of organism burden and alveolar macrophage counts during infection with Pneumocystis carinii and recovery. Clin. Diagn. Lab. Immunol., 10:293-302.
8. Lasbury, M. E., Lin, P., Tschang, D., Durant, P. J. & Lee, C. H. 2004. Effect of bronchoalveolar lavage fluid from Pneumocystis carinii-infected hosts on phagocytic activity of alveolar macrophages. Infect. Immun, 72:2140-2147.
9. Lasbury, M. E., Durant, P. J., Ray, C. A., Tschang, D., Schwendener, R. & Lee, C. H. 2006. Suppression of alveolar macrophage apoptosis prolongs survival of rats and mice with Pneumocystis pneumonia. J. Immunol., 176:6443-6453.
10. Lundberg, B. E., Davidson, A. J. & Burman, W. J. 2000. Epidemiology of Pneumomcystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure. AIDS, 14:2611-2612.
11. Moorman, A. C., von Bargen, J. C., Palella, F. J. & Holmberg, S. D. 1998. Pneumocystis carinii pneumonia incidence and chemoprophylaxis failure in ambulatory HIV-infected patients. HIV outpatient study (HOPS) investigators. J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., 19:182-188.
12. Park, C. B., Kim, M. S. & Kim, S. C. 1996. A novel antimicrobial peptide from Bufo bufo gargarizans. Biochem. Biophys. Res. Commun., 218:408-413.
13. Park, C. B., Yi, K. S., Matsuzaki, K., Kim, M. S. & Kim, S. C. 2000. Structure-activity analysis of buforin II, a histone H2A-derived antimicrobial peptide: the proline hinge is responsible for the cell-penetrating ability of buforin II. Proc. Natl. Acad. Sci. USA, 97:8245-8250.
14. Raviglione, M. C. 1990. Extrapulmonary pneumocystis: the first 50 cases. Rev. Infect Dis., 12:1127-1138.